The safety of prehospital naloxone administration by paramedics

Yealy, Donald M.; Paris, Paul M.; Kaplan, Richard M; Heller, Michael; Marini, Sal E

doi:10.1016/s0196-0644(05)81566-5

Cited by 82 publications

(31 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the patient with known or suspected opioid overdose with respiratory depression who is not in cardiac arrest, ventilation should be assisted by a bag mask, [232][233][234][235][236][237][238] followed by administration of naloxone and placement of an advanced airway if there is no response to naloxone (Class I, LOE A).…”

Section: Opioid Toxicitymentioning

confidence: 99%

Part 12: Cardiac Arrest in Special Situations

Hoek¹,

Morrison²,

Shüster³

et al. 2010

Circulation

660

437

View full text Add to dashboard Cite

Section: Opioid Toxicitymentioning

confidence: 99%

Part 12: Cardiac Arrest in Special Situations

Hoek¹,

Morrison²,

Shüster³

et al. 2010

Circulation

660

437

View full text Add to dashboard Cite

“…Yealy and colleagues [Yealy et al 1990] performed a retrospective review of prehospital records to investigate the safety of naloxone administered by paramedics in the prehospital setting over a 1-year period.…”

Section: Naloxone Safety Profile After Parenteral Usementioning

confidence: 99%

Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access

Wermeling

2015

Therapeutic Advances in Drug Safety

134

101

View full text Add to dashboard Cite

Opioid overdose and mortality have increased at an alarming rate prompting new public health initiatives to reduce drug poisoning. One initiative is to expand access to the opioid antidote naloxone. Naloxone has a long history of safe and effective use by organized healthcare systems and providers in the treatment of opioid overdose by paramedics/ emergency medicine technicians, emergency medicine physicians and anesthesiologists. The safety of naloxone in a prehospital setting administered by nonhealthcare professionals has not been formally established but will likely parallel medically supervised experiences. Naloxone dose and route of administration can produce variable intensity of potential adverse reactions and opioid withdrawal symptoms: intravenous administration and higher doses produce more adverse events and more severe withdrawal symptoms in those individuals who are opioid dependent. More serious adverse reactions after naloxone administration occur rarely and may be confounded by the effects of other co-intoxicants and the effects of prolonged hypoxia. One component of the new opioid harm reduction initiative is to expand naloxone access to high-risk individuals (addicts, abusers, or patients taking high-dose or extended-release opioids for pain) and their close family or household contacts. Patients or their close contacts receive a naloxone prescription to have the medication on their person or in the home for use during an emergency. Contacts are trained on overdose recognition, rescue breathing and administration of naloxone by intramuscular injection or nasal spraying of the injection prior to the arrival of emergency medical personnel. The safety profile of naloxone in traditional medical use must be considered in this new context of outpatient prescribing, dispensing and treatment of overdose prior to paramedic arrival. New naloxone delivery products are being developed for this prehospital application of naloxone in treatment of opioid overdose and prevention of opioid-induced mortality.

show abstract

“…Serious adverse effects of naloxone are rare, and are likely related to the overdose rather than the medication, when administered in either clinical or street settings. [16][17][18][19][20][21][22][23] In March 2010, the Governor of the State of Washington signed overdose intervention legislation that permits the prescription and possession of naloxone, and administration to others suffering from opioid overdoses. 24 This legislation became effective in June 2010 and also includes another relatively uncommon overdose prevention measure in the US-limited immunity from prosecution for drug possession charges for individuals who overdose or seek medical assistance in drug overdoses.…”

Section: Introductionmentioning

confidence: 99%

Risk Factors for Nonfatal Overdose at Seattle-Area Syringe Exchanges

et al. 2011

View full text Add to dashboard Cite

Opioid-involved overdose deaths are on the rise, both nationwide and in the state of Washington. In a survey of 443 participants at syringe exchanges in Seattle, Washington, 16% had overdosed in the last year. Several factors were significantly associated in bivariate analysis: lack of permanent housing; incarceration of five or more days in the past year; gender of sex partners; sharing of syringes and other injection paraphernalia; use of speedballs (cocaine and heroin together), goofballs (methamphetamine and heroin together), buprenorphine; injection use of crack cocaine and sedatives; and use of opioids with sedatives. Adjusting for other variables in multivariate logistic regression analyses, only recent incarceration and sharing of injection materials were still significantly associated with overdose. Correctional facilities, syringe exchange programs, and other agencies serving opioid injectors should include overdose prevention components in release planning and services.

show abstract

The safety of prehospital naloxone administration by paramedics

Cited by 82 publications

References 12 publications

Part 12: Cardiac Arrest in Special Situations

Part 12: Cardiac Arrest in Special Situations

Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access

Risk Factors for Nonfatal Overdose at Seattle-Area Syringe Exchanges

Contact Info

Product

Resources

About